Galápagos NV has extended for the third time a drug discovery agreement with Genentech (Roche) that involves the use of a number of technologies to discover new chemical entities against targets defined by the Roche group subsidiary. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
